Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) – Wedbush lowered their FY2024 EPS estimates for shares of Praxis Precision Medicines in a report issued on Wednesday, November 6th.
Wedbush believes the reaction post Q3 results is “overdone,” with shares now trading for 11.6-times its 2026 adjusted EBITDA estimate for a business that is set to grow adjusted EBITDA at a 2 News ...
Tempur Sealy International, Inc. (NYSE:TPX – Free Report) – Equities researchers at Wedbush lowered their FY2024 earnings per share estimates for shares of Tempur Sealy International in a ...
Wedbush analyst Daniel Ives maintained a Buy rating on Couchbase (BASE – Research Report) today and set a price target of $26.00. The company’s shares opened today at $19.05. Ives covers the ...
Wedbush Securities, a global independent financial services firm, announces the hire of Mike McCall as Senior Vice President, Investments and Market M ...
Tesla shares continued to add to their gains since the presidential election on optimism the electric vehicle maker will benefit from a Trump administration.